Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

Now Viewing

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Video content above is prompted by the following:

ASH 2024 Oncology Highlights for Physicians: Multiple Myeloma CAR T-Cell Therapy

Summary of Peer Exchange Discussion

An OncLive Peer Exchange focused on key data presented at the American Society of Hematology (ASH) 2024 Annual Meeting. The panel features experts:

• Andre Goy, MD
• Jamie Koprivnikar, MD
• Harsh Parmar, MD

The discussion aims to highlight significant abstracts and foster expert dialogue on recent developments in hematologic malignancies, specifically focusing on lymphoma, leukemia, and multiple myeloma.

The first abstract (#2408) under discussion examines real-world data comparing ciltacabtagene autoleucel (cilta-cel) vs idecabtagene vicleucel (ide-cel) in patients with relapsed multiple myeloma. Dr Parmar is invited to provide insights on how this real-world evidence might inform clinical decision-making for patients with multiple myeloma and potentially influence treatment selection between these 2 chimeric antigen receptor (CAR) T-cell therapies.

The discussion emphasizes the value of real-world data in understanding how approved therapies perform in clinical practice outside the controlled environment of clinical trials.